Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units

Executive Summary

• Devonian Health Group closed a non‑brokered private placement raising $334,500.33 through the issuance of 1,967,649 units at $0.17 per unit.
• Each unit includes one common share and one warrant to purchase an additional share at $0.17 for 24 months.
• Proceeds will be used primarily for working‑capital needs related to corporate overhead and R&D activities.
• CEO Dr. André Boulet will present Devonian’s business at the ThinkEquity Conference in New York on October 30, 2025.

Key Details

• Private Placement Structure: 1,967,649 units @ $0.17 per unit = $334,500.33 gross proceeds.
• Unit Composition: 1 common share + 1 warrant (exercise price $0.17, exercisable for 24 months).
• Use of Proceeds: Finance working capital, corporate overhead, and research & development programs.
• Fees Paid: Cash finder’s fees of $14,166.68 incurred in connection with the offering.
• Restriction Period: Shares and warrants subject to a hold period of four months + one day, ending February 23, 2026 under Canadian securities law.
• Regulatory Condition: Offering remains subject to final approval by the TSX Venture Exchange.
• Conference Participation: Dr. André Boulet (Chairman & CEO) scheduled to present at ThinkEquity Conference, Mandarin Oriental, New York City, 12:30 pm, October 30, 2025.

Notable Quotes

(No direct quotes were provided in the release.)